Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial

K. L. Tedesco, A. D. Thor, David H. Johnson, Y. Shyr, K. A. Blum, L. J. Goldstein, W. J. Gradishar, B. P. Nicholson, D. E. Merkel, D. Murrey, S. Edgerton, G. W. Sledge

Research output: Contribution to journalArticlepeer-review

95 Scopus citations

Fingerprint Dive into the research topics of 'Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences